Skip to main content

Azora Therapeutics, Inc.

corporate_fare Company Profile

Azora Therapeutics, Inc.

ADIL·NASDAQ·Life Sciences·CIK 0001513525

We are a clinical-stage biopharmaceutical company focused on developing treatments for addiction and related disorders. Our primary investigational drug candidate, AD04, is being developed to treat alcohol use disorder (AUD). AD04 was studied in a Phase 3 clinical trial, called the ONWARD trial, for AUD in patients with specific genetic profiles identified using our companion diagnostic genetic test. We are now concentrating on completing the clinical development program for AD04 in these genetic subgroups to meet regulatory requirements, primarily in the US and secondarily in Europe/UK. The vast majority of our resources have been dedicated to AD04's development, including preparing for and conducting clinical trials, providing general and administrative support, and protecting our intellectual property. We anticipate these activities will continue to require most of our resources. We do not currently have any products approved for sale and have not generated significant revenue since our inception. Our operations have been funded primarily through private and public placements of debt, equity securities, and an equity line. Our current cash and cash equivalents are not expected to fund operations for the twelve months from the date of filing this Annual Report on Form 10-K. We have incurred net losses every year since inception, including approximately $8.0 million for the year ended December 31, 2025, and $13.2 million for the year ended December 31, 2024. Our accumulated deficits were approximately $90.0 million as of December 31, 2025, and $82.0 million as of December 31, 2024.

Azora Therapeutics, Inc. (NASDAQ:ADIL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 37 items for ADIL at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • ADIAL Completes Reverse Merger with Azora, Secures $25.3M Initial Financing, Faces Extreme Dilution
  • Adial Pharmaceuticals Announces Azora Therapeutics Acquisition, Up To $64M Financing
  • ADIAL PHARMACEUTICALS Reports Q1 Loss, Confirms Limited Cash Runway, Advances AD04 with FDA Policy Shifts & Molteni Deal
  • Adial Pharmaceuticals Eyes Faster AD04 Approval on FDA Policy Shift, Reports Q1
  • Going Concern Warning Reiterated Amidst Significant Dilution; Cash Runway Remains Short
$4.86
Market cap
$13.26M
Volume
99.7K (2.6× avg)
3-mo avg 38.6K
Last traded · 2026-10-29

show_chartPrice Chart

Loading chart...

feed ADIL - Filings & News (Page 2)

ADIL
Jun 11, 2026, 12:43 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.29
Real-time Price: $4.86 info
Change: +$1.57 (+48%) info
Market Cap: $13.261M info
ADIL
Jun 11, 2026, 11:43 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $2.13
Real-time Price: $4.86 info
Change: +$2.73 (+128%) info
Market Cap: $13.261M info
ADIL
May 11, 2026, 8:40 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.48
Real-time Price: $4.86 info
Change: +$3.38 (+228%) info
Market Cap: $13.261M info
ADIL
May 11, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.48
Real-time Price: $4.86 info
Change: +$3.38 (+228%) info
Market Cap: $13.261M info
ADIL
May 08, 2026, 4:21 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.43
Real-time Price: $4.86 info
Change: +$3.43 (+240%) info
Market Cap: $13.261M info
ADIL
Apr 29, 2026, 9:07 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.64
Real-time Price: $4.86 info
Change: +$3.22 (+196%) info
Market Cap: $13.261M info
ADIL
Apr 22, 2026, 9:35 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.59
Real-time Price: $4.86 info
Change: +$3.27 (+206%) info
Market Cap: $13.261M info
ADIL
Apr 09, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.58
Real-time Price: $4.86 info
Change: +$3.28 (+208%) info
Market Cap: $13.261M info
ADIL
Mar 24, 2026, 9:07 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.90
Real-time Price: $4.86 info
Change: +$2.96 (+156%) info
Market Cap: $13.261M info
ADIL
Mar 06, 2026, 8:15 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.97
Real-time Price: $4.86 info
Change: +$2.89 (+147%) info
Market Cap: $13.261M info
ADIL
Mar 06, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $1.99
Real-time Price: $4.86 info
Change: +$2.87 (+144%) info
Market Cap: $13.261M info
ADIL
Mar 05, 2026, 5:05 PM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.93
Real-time Price: $4.86 info
Change: +$2.93 (+152%) info
Market Cap: $13.261M info
ADIL
Mar 05, 2026, 5:03 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $1.90
Real-time Price: $4.86 info
Change: +$2.96 (+156%) info
Market Cap: $13.261M info
ADIL
Mar 03, 2026, 8:17 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.42
Real-time Price: $4.86 info
Change: +$2.44 (+101%) info
Market Cap: $13.261M info
ADIL
Feb 24, 2026, 9:06 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.55
Real-time Price: $4.86 info
Change: +$2.31 (+91%) info
Market Cap: $13.261M info
ADIL
Feb 04, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.1584
Real-time Price: $4.86 info
Change: Reverse Stock Split info
Market Cap: $13.261M info
ADIL
Jan 06, 2026, 4:15 PM EST
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $0.2521
Real-time Price: $4.86 info
Change: Reverse Stock Split info
Market Cap: $13.261M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets